Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Dolan

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|September 12, 2001
Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporationM H Wu, S L Smith, G H Danet, et al.
Cancer Research|September 1, 1994
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenograftsM E Dolan, M J Fleig, B G Feuerstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patientsA B Benson, O I Olopade, M J Ratain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancerR L Schilsky, M E Dolan, D Bertucci, et al.
Biochemical Pharmacology|June 20, 1998
O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterasesM E Dolan, S K Roy, B J Garbiras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agentE Gupta, O I Olopade, M J Ratain, et al.
Cancer Research|July 1, 1995
Activity of temozolomide in the treatment of central nervous system tumor xenograftsH S Friedman, M E Dolan, A E Pegg, et al.
Anti-Cancer Drugs|July 11, 1998
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agentsM E Dolan, B Frydman, C B Thompson, et al.
Journal of the National Cancer Institute|December 26, 1992
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiformeH S Friedman, M E Dolan, R C Moschel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancerR A Humerickhouse, M E Dolan, D J Haraf, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|September 12, 2001
Optimization of culture conditions to enhance transfection of human CD34+ cells by electroporationM H Wu, S L Smith, G H Danet, et al.
Cancer Research|September 1, 1994
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenograftsM E Dolan, M J Fleig, B G Feuerstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patientsA B Benson, O I Olopade, M J Ratain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancerR L Schilsky, M E Dolan, D Bertucci, et al.
Biochemical Pharmacology|June 20, 1998
O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterasesM E Dolan, S K Roy, B J Garbiras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agentE Gupta, O I Olopade, M J Ratain, et al.
Cancer Research|July 1, 1995
Activity of temozolomide in the treatment of central nervous system tumor xenograftsH S Friedman, M E Dolan, A E Pegg, et al.
Anti-Cancer Drugs|July 11, 1998
Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agentsM E Dolan, B Frydman, C B Thompson, et al.
Journal of the National Cancer Institute|December 26, 1992
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiformeH S Friedman, M E Dolan, R C Moschel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancerR A Humerickhouse, M E Dolan, D J Haraf, et al.
Pageof 12